Radiotherapy in well-differentiated thyroid cancer: is it underutilized?

Area of Science:

• Oncology
• Radiotherapy
• Endocrinology

Background:

• Standard thyroid cancer treatment involves surgery and radioactive iodine.
• The role of external beam radiotherapy (EBRT) in well-differentiated thyroid carcinoma is debated.
• EBRT is indicated for unresectable, non-iodine avid, locally advanced, or metastatic disease.

Purpose of the Study:

• To evaluate the efficacy of external beam radiotherapy (EBRT) in managing well-differentiated thyroid carcinoma.
• To assess tumor and symptom control in patients treated with EBRT.

Main Methods:

• Retrospective review of prospectively collected data from a single Australian institution.
• Analysis of patients treated with EBRT for well-differentiated thyroid carcinoma between November 1992 and July 2013.
• Inclusion criteria focused on patients referred and treated with EBRT.

Main Results:

• 32 out of 36 referred patients were treated with EBRT.
• Locoregional EBRT in 16 patients (often with recurrent, advanced disease) showed high rates of asymptomatic control (88% at last follow-up).
• EBRT for bone metastases resulted in 93% and 78% symptom-free rates at two and four years, respectively.

Conclusions:

• External beam radiotherapy (EBRT) provides durable tumor and symptom control in select well-differentiated thyroid carcinoma patients.
• EBRT is a valuable option for managing complex cases, including recurrent or unresectable disease.
• The study supports EBRT's role in improving quality of life for thyroid cancer patients.